Active Stocks
Tue Mar 19 2024 15:21:08
  1. Tata Consultancy Services share price
  2. 3,974.15 -4.12%
  1. Tata Steel share price
  2. 148.85 -0.50%
  1. Bharti Airtel share price
  2. 1,224.85 -0.02%
  1. Power Grid Corporation Of India share price
  2. 259.05 -2.25%
  1. ITC share price
  2. 409.80 -1.82%
Business News/ Industry / Manufacturing/  Biocon launches biosimilar bevacizumab for cancer treatment in India
BackBack

Biocon launches biosimilar bevacizumab for cancer treatment in India

Biocon's biosimilar bevacizumab is indicated as a first-line treatment of patients with metastatic colorectal cancer and also used to treat lung, kidney, cervical, ovarian and brain cancers

Krabeva is Biocon’s second biosimilar for cancer treatment introduced in India.Premium
Krabeva is Biocon’s second biosimilar for cancer treatment introduced in India.

Mumbai: Biocon Ltd on Thursday said it has launched biosimilar bevacizumab, used to treat several types of cancer, under the brand name Krabeva in India, at Rs24,000 for 100 mg/4 ml vials and Rs39,990 for 400 mg/16 ml vials.

Krabeva is Biocon’s second biosimilar for cancer treatment introduced in India. It is indicated as a first-line treatment of patients with metastatic colorectal cancer and also used to treat lung, kidney, cervical, ovarian and brain cancers.

Currently, bevacizumab is sold in India by innovator Roche under the name Avastin and biosimilar versions of the drug by Intas Pharmaceuticals Ltd, Hetero Healthcare Ltd, Cadila Healthcare Ltd and Lupin Ltd, according to data from market research firm AIOCD-AWACS.

The price of Roche Avastin for 100 mg is Rs41,250. The biosimilars from various companies are available in the range of Rs22,000 to Rs27,100, as per the AIOCD-AWACS data.

Krabeva is being launched post successful completion of phase-III clinical trials and approval from the Drug Controller General of India (DCGI), the Bengaluru-based company said in a press release, adding that the product has a unique ‘Qual-Check’ mechanism, which will ensure that patients get a quality-ascertained product right up to infusion and a temperature-sensitive packaging.

Incidence of cancer is likely to reach alarming numbers with over 17.3 lakh new cases of cancer and over 8.8 lakh cancer deaths projected in India by 2020 as per the Indian Council of Medical Research (ICMR).

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Industry News, Banking News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 23 Nov 2017, 10:57 PM IST
Next Story footLogo
Recommended For You
Manufacturing Stocks
₹530.60.34%
ITC
₹417.4-1.8%
₹2,878.35-0.94%
₹1,571.45-1.71%
₹149.6-0.57%
Switch to the Mint app for fast and personalized news - Get App